A5028130303- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- Hepatitis C virus research
- COVID-19 Clinical Research Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Cytomegalovirus and herpesvirus research
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- Liver Disease Diagnosis and Treatment
- SARS-CoV-2 detection and testing
- T-cell and B-cell Immunology
- Cervical Cancer and HPV Research
- Long-Term Effects of COVID-19
- vaccines and immunoinformatics approaches
- Herpesvirus Infections and Treatments
- COVID-19 epidemiological studies
- Pharmacological Effects and Toxicity Studies
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- interferon and immune responses
- HIV, Drug Use, Sexual Risk
Universitat Autònoma de Barcelona
2016-2025
Universitat de Vic - Universitat Central de Catalunya
2016-2025
IrsiCaixa
2016-2025
Hospital Universitari Germans Trias i Pujol
2016-2025
Centro de Investigación Biomédica en Red
2021-2025
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2016-2025
Institut Català de la Salut
2020-2025
Instituto de Salud Carlos III
2000-2025
Fundació Lluita contra les Infeccions
2015-2024
Fundació ACE
2023-2024
<h3>Importance</h3> A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral therapy (ART) as a prevention strategy is absolute risk HIV transmission through condomless sex with suppressed HIV-1 RNA viral load for both anal vaginal sex. <h3>Objective</h3> To evaluate rate within-couple (heterosexual men who have [MSM]) during periods without condoms when HIV-positive partner had less than 200 copies/mL. <h3>Design, Setting, Participants</h3> The prospective,...
Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral is correlated with poor virologic response to new therapy. The International AIDS Society-USA sought update prior recommendations provide guidance clinicians regarding indications HIV-1 testing.An 13-member physician panel expertise basic science, research, patient care involving HIV antiretroviral drugs was reconvened the use of testing.The...
CC chemokine receptor 5 antagonists are a new class of antiretroviral agents.We conducted two double-blind, placebo-controlled, phase 3 studies--Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2--with patients who had R5 human immunodeficiency virus type (HIV-1) only. They been treated with or resistance to three antiretroviral-drug classes HIV-1 RNA levels more than 5000 copies per milliliter. The were randomly assigned...
Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs.We conducted two identical trials in different geographic regions evaluate the safety and efficacy raltegravir, as compared with placebo, combination optimized background therapy, patients infected that has triple-class drug resistance whom therapy had failed. Patients were randomly assigned raltegravir placebo a 2:1...
The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks treatment with fusion inhibitor enfuvirtide in combination an optimized background antiretroviral regimen alone.
Resistance to antiretroviral drugs remains an important limitation successful human immunodeficiency virus type 1 (HIV-1) therapy. testing can improve treatment outcomes for infected individuals. The availability of new from various classes, standardization resistance assays, and the development viral tropism tests necessitate guidelines testing. International AIDS Society-USA convened a panel physicians scientists with expertise in drug-resistant HIV-1, drug management, patient care review...
New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel physicians scientists with expertise in antiretroviral drug management, HIV-1 resistance, patient care provide updated recommendations testing. Published data presentations at scientific conferences, as well strength evidence, were considered. Properly used can improve virological outcome among...
We evaluated the efficacy of raltegravir and development viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) triple-class drug whom antiretroviral therapy had failed.
Scarce data are available on what variables affect the risk of transmission severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), development symptomatic COVID-19, and, particularly, relationship with viral load. We aimed to analyse from linked index cases COVID-19 and their contacts explore factors associated SARS-CoV-2.In this cohort study, patients were recruited as part a randomised controlled trial done between March 17 April 28, 2020, that assess if hydroxychloroquine reduced...
Objective: To characterize the safety profile of tenofovir disoproxil fumarate (DF) for treatment HIV infection in adults over first 4 years use. Methods: A DF expanded access program (EAP) was initiated 2001; data were examined from this and manufacturer's database, which contained reports all postmarketing adverse drug reactions received up to 30 April 2005. Specific analyses performed renal DF. Results: The EAP enrolled 10 343 patients; serious events (SAEs) reported 631 (6%). SAE any...
Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG HIV-1–infected subjects with genotypic evidence RAL resistance. Methods. Subjects received 50 mg once daily (cohort I) or twice II) while continuing failing regimen (without RAL) through day 10, after which background was optimized, when feasible, for...
No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious outpatients COVID-19.Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed <5-day of symptom onset were assigned receive HCQ (800 mg on day 1 followed by 400 once daily 6 days) or usual care. Outcomes reduction viral load nasopharyngeal...